---
run_id: halo-evidence-vs-diagnosis-validation-v12-generic-advice-prompted-06
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
model_condition: generic_advice_prompted
run_number: 6
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 2048
seed: 605
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 2d3cd0a66ac65ac18e241525d58fddd7447998bf4d887a6f8c7bfef16372a25d
condition_packet_sha256: 2d3cd0a66ac65ac18e241525d58fddd7447998bf4d887a6f8c7bfef16372a25d
output_file: model-outputs/generic_advice_prompted-06.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 06)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v12-v1`, condition `generic_advice_prompted`, run 6 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 605, on the frozen condition packet.

## Output

I recommend that you commit to the **Case Evidence Review**.

### Reasoning: The "False Positive" Trap
Your company is currently experiencing a dangerous alignment of lagging indicators. Expansion bookings are up, sales cycles are shorter, and executive sentiment is high. However, the leading indicators—the actual behavior of the end-users—are flashing red.

You have a classic "Sales-Product Gap." The buyers (executives) are buying the *promise* of PlanPilot, but the users (analysts) are struggling with its *utility*. The evidence suggests that PlanPilot is currently a "theatre" tool: managers use it for demos/enablement, and analysts use it as a starting template but quickly abandon it for manual notes. Most concerning is the public sector feedback: if an analyst cannot explain a recommendation to a reviewer, the tool is a liability, not an asset.

If you scale now, you are scaling a product that users find opaque and unreliable. This creates a "churn bomb" that will explode next year when the bundle pricing expires and procurement teams realize the tool isn't actually integrated into the daily workflow.

**Why the other options fail right now:**
*   **Scale Broadly:** High risk. You would be investing budget into a feature that may have zero long-term retention.
*   **Adoption Quality Sprint:** This measures *if* people are using it, but not *why* or *how*. You already know usage is up, but you suspect the usage is "empty" (e.g., rerunning samples). More dashboards won't tell you why an analyst reverts to manual notes.
*   **Demand Cleanroom:** This tests the *sales pitch*, not the *product*. While it would prove whether the bundle pricing is driving the growth, it doesn't fix the underlying product deficiency.
*   **Public-Sector Pivot:** Too premature. You don't yet know if the "explainability" problem is unique to the public sector or a systemic flaw in PlanPilot’s logic.

The **Case Evidence Review** is the only option that attacks the "Ground Truth." By auditing actual case files, you move from *proxy metrics* (clicks and bookings) to *outcome metrics* (accepted vs. overridden suggestions). This tells you exactly where the product is failing the user.

### The Trade-off
By choosing the Case Evidence Review, you are displacing the **Demand Cleanroom**.

**What you give up:** You sacrifice the ability to definitively prove whether your current revenue growth is "fake" (driven by pricing bundles and roadmap promises) or "real." You will enter next year with uncertainty regarding whether your sales team is over-promising, and you risk a dip in short-term expansion bookings because you aren't actively testing the removal of incentives.

### The Strongest Reason Against This Recommendation
The Case Evidence Review is slow and qualitative. While you are manually auditing files, the "momentum" praised by your executive team may stall. If the board is currently intoxicated by the 16% expansion growth, recommending a "deep dive into failure points" may be perceived as a lack of commercial aggression or a "product-mindset" that ignores the sales window.

### Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discovered that the "manual notes" fallback used by analysts is actually a company-wide industry standard (i.e., no competitor's tool replaces manual notes) and that the "explainability" issue in the public sector is a legal requirement that cannot be solved via software. In that case, the product isn't "broken"—it's just not a primary value driver—and your biggest risk would be the financial instability of the pricing bundles rather than the product's utility.
